We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Diagnostic Values of Serum STAT4 and sEng Analyzed in Preeclampsia

By LabMedica International staff writers
Posted on 06 Nov 2019
Preeclampsia is a pregnancy complication characterized by high blood pressure and signs of damage to another organ system, most often the liver and kidneys. More...
Preeclampsia usually begins after 20 weeks of pregnancy in women whose blood pressure had been normal.

Preeclampsia can cause serious complications such as cerebral edema, pulmonary edema, cerebral hemorrhage, heart failure, coagulopathy, liver rupture, placental abruption, fetal growth restriction, and fetal death. It is one of the main causes of increased perinatal mortality.

Medical laboratorians at the Ningbo Mingzhou Hospital (Ningbo, China) enrolled 54 pregnant women with preeclampsia from October 2017 to June 2018 and 28 matched healthy pregnant women were set as the control group. The preeclampsia patients were included following the criteria: (a) age 20‐40 years; (b) hypertension, proteinuria, and edema; and (c) singletons, all of which are terminated by cesarean section and are healthy in the past.

The purpose of the study was to detect the levels of signal transducer and activator of transcription 4 (STAT4) and soluble endoglin (sEng) in preeclampsia patients and analyze the diagnostic values of STAT4 and sEng in preeclampsia. The team used the testing method of sEng and STAT4 enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis, MN, USA). The related clinical indexes of the pregnant women in each group were detected, including the prothrombin time (PT), fibrinogen (Fib), 24‐hour urine protein, serum creatinine (SCr), and alanine transaminase (ALT) within a week before delivery. The relationship between serum STAT4 level and pregnant women in the mild and severe preeclampsia groups was also analyzed.

The scientists reported that compared with control, the prothrombin time in preeclampsia was significantly lower, while the mean arterial pressure, 24‐hour urine protein, serum creatinine, fibrinogen, and ALT were significantly higher. The circulating levels of STAT4 and sEng were significantly increased in the preeclampsia. The circulating levels of STAT4 were statistically significant difference: 0.340 ± 0.062, 0.637 ± 0.159, and 1.513 ± 0.182 ng/mL in the control group, mild preeclampsia group, and severe preeclampsia group. The circulating levels of sEng in serum were 8.982 ± 1.089, 11.421 ± 1.330, and 13.152 ± 1.735 ng/mL in the control group, mild preeclampsia group, and severe preeclampsia group, with statistically significant differences. The serum levels of STAT4 and sEng in preeclampsia were positively correlated.

The authors concluded that both STAT4 and sEng have diagnosis values for preeclampsia, but the sensitivity and specificity of STAT4 were better than sEng, suggesting STAT4 can be used as a novel serum marker for diagnosis of preeclampsia, and thus postponed the development of the disease. The study was published on October 19, 2019, in the Journal of Clinical Laboratory Analysis.

Related Links:
Ningbo Mingzhou Hospital
R&D Systems



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Host Response Immunoassay Test
MeMed BV
New
Silver Member
Quality Control Material
Multichem ID-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.